Person: SALMAN, ANDAÇ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SALMAN
First Name
ANDAÇ
Name
5 results
Search Results
Now showing 1 - 5 of 5
Publication Metadata only Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data(WILEY, 2021) SALMAN, ANDAÇ; Salman, Andac; Aktas, Meryem; Sengun, Ozlem AptiOmalizumab is a well-established treatment option in chronic spontaneous urticaria unresponsive to antihistamines at standard or higher doses. However, characteristics of the remission and relapse following the withdrawal of omalizumab remain largely unknown. We aimed to define the characteristics of remission in CSU following omalizumab with gradually lengthened dosing intervals in this retrospective study of 102 patients who were treated with at least 5 doses of omalizumab between 2015 and 2020. Of 102 patients, 70 (68.6%) showed a CR to omalizumab at standard doses. Omalizumab could be discontinued in 47 of 70 patients using gradually lengthened dosing intervals. Following a mean follow-up duration of 12.2 months, 25 (58.1%) patients were still in remission while 18 (41.9%) had relapse (Follow-up data were not available in 4 patients). The relapses were unresponsive to antihistamines in 14 patients (77.7%), however, retreatment with omalizumab led to complete control of symptoms. The patients younger than 40 were more likely to relapse. Despite the need for comparison with fixed-dosing intervals in larger, prospective studies, the results of this study imply that omalizumab with gradually extended dosing intervals might provide a long duration of remission in CSU.Publication Open Access Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology(DERI ZUHREVI HASTALIKLAR DERNEGI, 2020-06-29) SALMAN, ANDAÇ; Salman, Andac; Alper, Sibel; Atakan, Nilgun; Baskan, Emel Bulbul; Borlu, Murat; Canpolat, Filiz; Erdem, Teoman; Erdem, Yasemin; Gul, Ulker; Kartal, Selda Pelin; Koca, Rafet; Kucuk, Ozlem Su; Ogretmen, Zerrin; Ozkaya, Esen; Saricaoglu, Hayriye; Savk, Ekin; Taskapan, Oktay; Utas, Serap; Kocaturk, EmekPublication Open Access Omalizumab Treatment in Chronic Spontaneous Urticaria During Pregnancy: Report of A Case and Review of the Literature(BILIMSEL TIP YAYINEVI, 2021-08-23) SALMAN, ANDAÇ; Salman, Andac; Aktas, MeryemOmalizumab is a safe and effective treatment option for chronic spontaneous urticaria (CSU). Although cohort studies in patients with asthma show no increased risk of congenital abnormalities, very little data exist in the literature regarding the use of omalizumab for CSU during pregnancy. Herein, the safe and successful use of omalizumab updosing in a pregnant woman with CSU along with a review of the published literature is presented.Publication Open Access Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study(TAYLOR & FRANCIS LTD, 2020-02-17) SALMAN, ANDAÇ; Salman, Andac; Ergun, Tulin; Maria Gimenez-Arnau, AnaBackground: The real-life data on the effectiveness and safety of omalizumab in chronic spontaneous urticaria (CSU) with validated methods are scarce. There is also a lack of information on the use of combination treatments. Methods: A retrospective cohort study was done to evaluate the effectiveness and safety of omalizumab in real-life conditions. The patients with CSU treated with omalizumab between 2015 and 2018 were included. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT). Results: A total of 106 patients were included. A complete response (CR) (UAS7:0) and a well-controlled activity (WCA) (UAS7:1 to <6) were observed in 50 (47.2%) and 35 (33%) patients, respectively. The number of patients with an UCT score >= 12 was also significantly increased. Higher rates of CR/WCA were observed with omalizumab monotherapy compared to combination with antihistamines. The combination of dapsone, colchicine, and omalizumab provided additional benefit in a small group. Conclusion: Treatment with omalizumab provided a rapid and sustainable improvement in real-life settings. The use of omalizumab as monotherapy or combined with antihistamines does not show differences in the treatment response. The combination of omalizumab with immunomodulatory agents might be of benefit in selected cases.Publication Open Access The global impact of the COVID-19 pandemic on the management and course of chronic urticaria(WILEY, 2021-03) SALMAN, ANDAÇ; Kocaturk, Emek; Salman, Andac; Cherrez-Ojeda, Ivan; Criado, Paulo Ricardo; Peter, Jonny; Comert-Ozer, Elif; Abuzakouk, Mohamed; Agondi, Rosana Camara; Al-Ahmad, Mona; Altrichter, Sabine; Arnaout, Rand; Arruda, Luisa Karla; Asero, Riccardo; Bauer, Andrea; Ben-Shoshan, Moshe; Bernstein, Jonathan A.; Bizjak, Mojca; Boccon-Gibod, Isabelle; Bonnekoh, Hanna; Bouillet, Laurence; Brzoza, Zenon; Busse, Paula; Campos, Regis A.; Carne, Emily; Conlon, Niall; Criado, Roberta F.; de Souza Lima, Eduardo M.; Demir, Semra; Dissemond, Joachim; Gunaydin, Sibel Dogan; Dorofeeva, Irina; Ensina, Luis Felipe; Ertas, Ragip; Ferrucci, Silvia Mariel; Figueras-Nart, Ignasi; Fomina, Daria; Franken, Sylvie M.; Fukunaga, Atsushi; Gimenez-Arnau, Ana M.; Godse, Kiran; Goncalo, Margarida; Gotua, Maia; Grattan, Clive; Guillet, Carole; Inomata, Naoko; Jakob, Thilo; Karakaya, Gul; Kasperska-Zajac, Alicja; Katelaris, Constance H.; Kosnik, Mitja; Krasowska, Dorota; Kulthanan, Kanokvalai; Kumaran, M. Sendhil; Lang, Claudia; Ignacio Larco-Sousa, Jose; Lazaridou, Elisavet; Leslie, Tabi Anika; Lippert, Undine; Llosa, Oscar Calderon; Makris, Michael; Marsland, Alexander; Medina, Iris, V; Meshkova, Raisa; Palitot, Esther Bastos; Parisi, Claudio A. S.; Pickert, Julia; Ramon, German D.; Rodriguez-Gonzalez, Monica; Rosario, Nelson; Rudenko, Michael; Rutkowski, Krzysztof; Sanchez, Jorge; Schliemann, Sibylle; Sekerel, Bulent Enis; Serpa, Faradiba S.; Serra-Baldrich, Esther; Song, Zhiqiang; Soria, Angele; Staevska, Maria; Staubach, Petra; Tagka, Anna; Takahagi, Shunsuke; Thomsen, Simon Francis; Treudler, Regina; Vadasz, Zahava; Rodrigues Valle, Solange Oliveira; Van Doorn, Martijn B. A.; Vestergaard, Christian; Wagner, Nicola; Wang, Dahu; Wang, Liangchun; Wedi, Bettina; Xepapadaki, Paraskevi; Yucel, Esra; Zalewska-Janowska, Anna; Zhao, Zuotao; Zuberbier, Torsten; Maurer, MarcusIntroduction The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and Methods Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.